As for breast cancers that are both ER+ and HER2+, inhibition of HER2 alone enables potential compensatory escape pathways due to the bi-directional signaling (i.e., crosstalk) between these receptor signaling pathways, which can result in resistance to HER2-directed agents and eventual tumor growth8,24–28. The gene discussed is ESR1; the disease is breast cancer.